Adverse events and laboratory abnormalities were monitored over 35 days after the commencement of treatment in 45 open studies conducted in Europe, South America, Africa and Asia. These studies were to assess the clinical efficacies of azithromycin and comparator antimicrobial agents in the treatment of paediatric acute bacterial infections. Children (6 months-16 years of age) had been treated with an oral suspension of azithromycin (10 mg/kg given once daily for 3 consecutive days) or with the approved oral dosing regimen of the comparator (amoxycillin, co-amoxiclav, cefixime, cefaclor, clarithromycin, erythromycin, penicillin V, cloxacillin, or roxithromycin). Adverse events were recorded in 232/2655 (8.7%) children treated with azithromycin and in 180/1844 (9.8%) who received comparator treatment. The majority of the treatment-related adverse events were classed as being of only mild or moderate severity and were gastrointestinal: 140 (5.3%) in azithromycin-and 120 (6.5%) in comparator-treated children. Co-amoxiclav was responsible for proportionately more of such events than any other agent. Treatment was discontinued prematurely due to an adverse event in 34 (1.3%) azithromycinand in 31 (1.7%) comparator-treated children. Incidences of clinically significant laboratory abnormalities were low and occurred with comparable frequency in both treatment groups. The present analysis confirms that azithromycin can be safely used to treat bacterial infections in children of all ages.
Introduction
The semisynthetic derivative of the macrolide erythromycin, azithromycin, has a methyl-substituted nitrogen incorporated into the 14-membered macrolide ring of the parent compound. In-vitro studies have shown that azithromycin possesses good activity against commonly occurring Gram-positive aerobic pathogens, including Streptococcus pneumoniae, Streptococcus pyogenes and Staphylococcus aureus (Aronoff, Laurent & Jacobs, 1987; Dunkin, Jones & Howard, 1988; Feraandes & Hardy, 1988; Neu et al., 1988) . In addition, compared with erythromycin, azithromycin has enhanced in-vitro activity against Gram-negative pathogens: for example, azithromycin's activity is two-to four-fold greater than that of erythromycin against Haemophilus influenzae (Retsema et al., 1987; Hardy et al., 1988; Goldstein et al., 1990) .
In animals, azithromycin has been found to be rapidly and extensively distributed in tissues , and studies in humans have shown that, when azithromycin is given orally, within 1 h, concentrations in a wide range of tissues including tonsils, lung and sinus exceed those in serum (Foulds, Shepard & Johnson, 1990) . Elimination from the tissues is slow; thus, sustained tissue concentrations are maintained for several G. Treadway and D. Pontani days after dosing. In adults, concentrations are projected to remain above 3 mg/kg for several days following a standard 1.5-mg dose. Studies have also shown that, up to 48 h after oral administration, concentrations of azithromycin in upper respiratory tract tissues of children exceed the MICs for many pathogens that commonly infect these sites (Pukander & Rautianen, 1996; Vaudaux, Cherpillod & Dayer, 1996) . This novel pharmacokinetic profile means that effective dosing can be achieved if the azalide is given only once daily for a short duration, compared with the standard dosing regimen of erythromycin which is four times daily for 10 days.
In addition to erythromycin having the disadvantage of a complex and extended dosing regimen compared with azithromycin, the parent macrolide is associated with a high incidence of gastrointestinal side-effects; nausea, diarrhoea and vomiting are frequently experienced by patients treated with erythromycin (Washington & Wilson, 1985) . This is thought to be due to the stimulation of gastric motility. The addition of a methyl-substituted nitrogen to the erythromycin macrocyclic structure may provide an explanation for the relatively low incidence of gastrointestinal side-effects associated with azithromycin (Hopkins, 1991 (Hopkins, , 1993 (Hopkins, , 1994 .
Animal toxicological studies have not detected any major abnormalities when high dosages of azithromycin are administered, and Phase I studies in healthy adults have demonstrated that azithromycin is associated with a low incidence of adverse events. Subsequent Phase II and Phase III studies have confirmed that azithromycin is well tolerated by adult patients of all ages (Hopkins, 1991 (Hopkins, , 1994 and by children (Hopkins, 1993) when used to treat bacterial infections, such as those of the upper and lower respiratory tracts and skin and soft tissues.
In this paper, data on the incidence and severity of side-effects and laboratory abnormalities recorded in large-scale comparative clinical trials conducted worldwide in children are summarized.
Patients and methods
Safety data obtained from open, randomized comparative paediatric clinical trials conducted in Europe, South America, Africa and Asia were assessed. The children, who were of either sex and between the ages of 6 months and 16 years, had been treated with azithromycin or a comparator antibacterial agent for suspected or confirmed bacterial infections. Azithromycin (10 mg/kg) had been administered orally as a suspension once daily for 3 consecutive days. The children who were treated with comparator antibacterial agents had received the approved oral dosing regimens.
Prior to enrolment in these studies, informed consent was obtained from the parents or guardians of all patients. After the initiation of therapy, all children were closely monitored by the investigators. Details of all adverse events, whether reported spontaneously by the patient, parent or guardian, or observed by the investigator, were recorded for up to 35 days after treatment had commenced, together with the perceived relationship to the study drug. In addition, details of the severity of each event (mild, moderate or severe), the organ system(s) involved, the time of onset, duration and any additional treatment required were documented.
Blood and urine samples were obtained from all patients before the start of antibacterial treatment for haematological and biochemical investigations and urinalysis respectively. Laboratory safety profiles were repeated after the completion of therapy. Laboratory test abnormalities were classified according to whether or not they were related to therapy.
Statistical analysis
The total incidence of adverse events in the two treatment groups was compared by the chi-squared test with continuity correction. All statistical tests were two-tailed and performed at the 0.05% significance level.
Results
In 43 studies, a total of 2655 children had been treated with azithromycin and 1844 children had received one of the following comparator agents: amoxycillin (114); co-amoxiclav (643); cefaclor (364); penicillin V (276); erythromycin (270); clarithromycin (7); cefixime (15); cloxacillin (163); and roxithromycin (1). Demographic details of the patients included in the safety data analysis are summarized in Table I . The children in the azithromycin and comparator treatment groups were all between the ages of 6 months and 16 years, with a similar proportion in both treatment groups below the age of 2 years. In both treatment groups, there was an higher proportion of males than females; the ratio of males to females was similar for the azithromycin and comparator groups. Also, the majority of patients enrolled were treated with either azithromycin or a comparator drug for upper respiratory tract infections (acute otitis media and streptococcal pharyngitis, in particular). Other children included in these studies had acute lower respiratory tract infections, including atypical pneumonia, and skin and soft tissue infections. The distribution of patients according to disease was similar in the azithromycin and comparator treatment groups.
In the azithromycin treatment group, adverse events considered to be related or possibly related to the treatment were experienced by 232/2655 (8.7%) children, whereas in the comparator group 180/1844 (9.8%) patients experienced adverse event (Table II) . The difference in the incidence of adverse events was not significantly different Gastrointestinal tract disorders (abdominal pain, diarrhoea, vomiting and/or nausea) were the most commonly reported events, occurring in 139 (5.2%) azithromycin-treated children. Among the treatment-related adverse events experienced by children receiving a comparator agent, 120 had one or more gastrointestinal disorders the most common events being diarrhoea, nausea and vomiting. Other gastrointestinal events (constipation, anorexia, abnormal stools, dyspepsia, jaundice, gastritis, gastroenteritis, melaena and oral candidosis) occurred with frequencies of less than 1% each in patients treated with azithromycin or any of the comparators and were generally not considered by the investigators to be related to treatment. Adverse events affecting the skin and considered by the investigators to be associated with treatment (rash or erythema multiforme) occurred with comparable frequency in patients receiving azithromycin (29 patients, 1.1%) or a comparator (25 patients, 1.4%). The incidence of treatment-related events associated with the CNS (headache and dizziness) was similar in both treatment groups: six (0.2%) azithromycin-treated children and three (0.2%) children who had received a comparator. The percentage of children receiving either treatment who experienced events associated with other body systems was very low (< 1%) and these experiences were not considered by the investigators to be treatment related.
When the incidences of adverse events for the individual comparator agents were considered, there was a wide variation in the percentages of children experiencing treatment-related adverse events (Table III) . Of the comparator agents, co-amoxiclav was associated with a particularly high incidence of adverse events. All but seven of the events in children who were treated with co-amoxiclav were gastrointestinal in nature. For the other comparators the nature of the adverse events were comparable to those associated with azithromycin.
The majority of the treatment-related adverse events in children to whom azithromycin was given were classified as mild or moderate, and did not result in the withdrawal of therapy (Table II) . Treatment was discontinued as a result of a treatment-related adverse event in 34 (1.3%) to whom azithromycin had been administered and in 31 (1.8%) who had received a comparator; the difference in incidence between the two treatment groups was not statistically significant (P > 0.05).
The monitoring of laboratory abnormalities was not performed in all studies. Table IV summarizes those abnormalities that were considered clinically significant and that were possibly related to treatment. There were no marked differences in the incidence of laboratory abnormalities in the two treatment groups, although the incidence of abnormal white cell and platelet counts tended to be higher in the comparator group. Both in children treated with azithromycin or with comparator, the most common laboratory abnormality was an abnormal neutrophil count. Treatment was not discontinued in any child prematurely due to an abnormal laboratory test.
Discussion
The data from 45 studies conducted worldwide shows that azithromycin is well tolerated by children when given as an oral suspension once daily for 3 days for the treatment of acute bacterial infections, including upper and lower respiratory tract infections and skin or soft tissue infections.
Previous analyses have demonstrated that 3-or 5-day, once-daily courses of azithromycin given to patients of all ages, including children (Hopkins, 1991 (Hopkins, , 1994 and to children between 7 months and 15 years of age (Hopkins, 1993) were well tolerated. This safety analysis includes studies conducted in children who were less than 6 months old and reports on events in children treated with 3-day, once-daily azithromycin In common with previous reports based on studies performed in patients of all ages, events associated with the gastrointestinal tract were the most common in both the azithromycin and comparator groups. The incidence of such events was generally comparable in azithromycin-treated patients and in those receiving comparator agents, with the exception of co-amoxiclav, which was associated with a higher incidence of such events, as has previously been observed by Hopkins (1993) . Events involving the skin and CNS were considerably less common than effects on the gastrointestinal system in children treated with either azithromycin or comparator.
The current analysis also confirmed the findings of Hopkins (1993) that the severity of events was generally only mild or moderate when children were treated with azithromycin. As a consequence of the relatively mild nature of the events, the incidence of premature discontinuation of treatment was low in azithromycin-treated children and was similar to that resulting from treatment with comparators.
Previous analyses have not detected any consistent effect on laboratory abnormalities in adults or children treated once daily with azithromycin for 3 or 5 days. Laboratory tests were not performed in all studies included in the present analysis, but in those where tests were carried out routinely, clinically significant variations in serum chemistry and haematology considered to be possibly due to treatment were detected only very infrequently. None of laboratory abnormalities was severe and all were only transient in nature.
The conclusions drawn from these studies are that azithromycin given as a suspension once daily for 3 days is well tolerated and can be used safely for the treatment of acute bacterial infections in children of all ages. Even in very young children, there are no concerns regarding safety or tolerance.
